AR117861A1 - Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry - Google Patents

Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry

Info

Publication number
AR117861A1
AR117861A1 ARP200100155A ARP200100155A AR117861A1 AR 117861 A1 AR117861 A1 AR 117861A1 AR P200100155 A ARP200100155 A AR P200100155A AR P200100155 A ARP200100155 A AR P200100155A AR 117861 A1 AR117861 A1 AR 117861A1
Authority
AR
Argentina
Prior art keywords
fabry
patients
disease
reduction methods
cerebrovascular event
Prior art date
Application number
ARP200100155A
Other languages
English (en)
Spanish (es)
Inventor
Hjalmar Lagast
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69726736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117861(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AR117861A1 publication Critical patent/AR117861A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
ARP200100155A 2019-01-22 2020-01-22 Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry AR117861A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962795524P 2019-01-22 2019-01-22

Publications (1)

Publication Number Publication Date
AR117861A1 true AR117861A1 (es) 2021-09-01

Family

ID=69726736

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100155A AR117861A1 (es) 2019-01-22 2020-01-22 Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry

Country Status (17)

Country Link
US (1) US20220087993A1 (https=)
EP (2) EP4523750A3 (https=)
JP (2) JP7680356B2 (https=)
AR (1) AR117861A1 (https=)
DK (1) DK3914247T3 (https=)
ES (1) ES3007212T3 (https=)
FI (1) FI3914247T3 (https=)
HR (1) HRP20250078T1 (https=)
HU (1) HUE069934T2 (https=)
LT (1) LT3914247T (https=)
PL (1) PL3914247T3 (https=)
PT (1) PT3914247T (https=)
RS (1) RS66410B1 (https=)
SI (1) SI3914247T1 (https=)
SM (1) SMT202500034T1 (https=)
TW (1) TW202042812A (https=)
WO (1) WO2020154354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Also Published As

Publication number Publication date
PT3914247T (pt) 2025-01-23
PL3914247T3 (pl) 2025-04-14
EP3914247B1 (en) 2024-11-13
ES3007212T3 (en) 2025-03-19
FI3914247T3 (fi) 2025-02-16
RS66410B1 (sr) 2025-02-28
LT3914247T (lt) 2025-01-27
SI3914247T1 (sl) 2025-03-31
HRP20250078T1 (hr) 2025-03-28
DK3914247T3 (da) 2025-01-27
SMT202500034T1 (it) 2025-03-12
HUE069934T2 (hu) 2025-04-28
EP3914247A1 (en) 2021-12-01
WO2020154354A1 (en) 2020-07-30
JP2022518733A (ja) 2022-03-16
EP4523750A3 (en) 2025-06-11
JP2025128105A (ja) 2025-09-02
US20220087993A1 (en) 2022-03-24
TW202042812A (zh) 2020-12-01
JP7680356B2 (ja) 2025-05-20
EP4523750A2 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
CO2018006358A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
MX361741B (es) Tratamientos médicos a base de anamorelina.
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
WO2018044132A3 (ko) 발기부전 환자를 위한 콘돔
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
CL2021000444A1 (es) Métodos para reducir el riesgo de diabetes en pacientes tratados por enfermedades relacionadas con el colesterol alto.
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure